Spectradyne
Dr Fraikin developed the initial NPA technology during his PhD thesis work at UC Santa Barbara in Dr. Cleland's research group. He has worked in cancer cell biology and biochemistry, and at InDevR led prototyping efforts for a microfluidics-based molecular diagnostic platform. At Spectradyne, Dr Fraikin previously led the development of instrument fluidics, software, and system integration. He is now serving as Spectradyne's CEO.
This person is not in any offices
Spectradyne
Spectradyne's particle analysis platform, the nCS1, is rapidly being adopted as a powerful and significantly more accurate alternative to light scattering-based methods of particle analysis.